IL1A and COVID-19: The efficiency of the COVID-19 vaccine may be expected to be lower in patients treated with IL-1 blockade, but limited evidence shows that patients with chronic rheumatic diseases under immunosuppression with either anti-TNF agents or IL-17 blockade develop adequate levels of antibody responses.